## **Gregory J Dore**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665452/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	IL28B is associated with response to chronic hepatitis C interferon- $\hat{1}\pm$ and ribavirin therapy. Nature Genetics, 2009, 41, 1100-1104.	21.4	1,808
2	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
3	Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 553-562.	17.8	833
4	Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis, 2006, 13, 34-41.	2.0	715
5	Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology, 2008, 48, 418-431.	7.3	714
6	Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 2001, 34, 809-816.	7.3	526
7	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 2013, 58, 1598-1609.	7.3	431
8	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2014, 384, 403-413.	13.7	431
9	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of Hepatology, 2017, 67, 1204-1212.	3.7	390
10	Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. Aids, 1999, 13, 1249-1253.	2.2	382
11	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 2014, 21, 34-59.	2.0	372
12	Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Annals of Internal Medicine, 2015, 163, 215-223.	3.9	364
13	Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine, 2018, 378, 354-369.	27.0	361
14	Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids, 2008, 22, 1979-1991.	2.2	348
15	Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. Annals of Internal Medicine, 2016, 165, 625.	3.9	322
16	The effects of female sex, viral genotype, and <i>IL28B</i> genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology, 2014, 59, 109-120.	7.3	320
17	Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2013, 57, S80-S89.	5.8	280
18	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. Journal of Hepatology, 2017, 67, 263-271.	3.7	261

#	Article	IF	CITATIONS
19	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naÃ <sup>-</sup> ve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology, 2013, 58, 1918-1929.	7.3	255
20	Hepatitis Bâ€related hepatocellular carcinoma: epidemiological characteristics and disease burden. Journal of Viral Hepatitis, 2009, 16, 453-463.	2.0	252
21	Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy–Naive and –Experienced Patients Coinfected with HIVâ€1 and Hepatitis B Virus. Journal of Infectious Diseases, 2004, 189, 1185-1192.	4.0	237
22	Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet, The, 2006, 368, 938-945.	13.7	237
23	Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLYâ€3+). Hepatology, 2016, 63, 1430-1441.	7.3	232
24	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 153-161.	8.1	231
25	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology, 2017, 153, 113-122.	1.3	215
26	Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. Aids, 2003, 17, 1539-1545.	2.2	212
27	Historical epidemiology of hepatitis C virus ( <scp>HCV</scp> ) in selected countries. Journal of Viral Hepatitis, 2014, 21, 5-33.	2.0	211
28	Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ: British Medical Journal, 1998, 317, 433-437.	2.3	203
29	Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection. PLoS Pathogens, 2011, 7, e1002243.	4.7	201
30	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. Journal of Hepatology, 2017, 66, 910-918.	3.7	192
31	Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infectious Diseases, The, 2012, 12, 408-414.	9.1	186
32	Global, regional, and countryâ€level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	3.3	178
33	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 754-767.	8.1	174
34	Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. Journal of Infectious Diseases, 2013, 207, S19-S25.	4.0	165
35	Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 2003, 26, 171-184.	3.1	162
36	Strategies to manage hepatitis <scp>C</scp> virus ( <scp>HCV</scp> ) disease burden. Journal of Viral Hepatitis, 2014, 21, 60-89.	2.0	161

#	Article	IF	CITATIONS
37	Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. Aids, 2006, 20, 863-870.	2.2	159
38	Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 1028-1038.	3.3	159
39	Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. International Journal of Drug Policy, 2017, 47, 34-46.	3.3	158
40	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 123-135.e2.	1.3	157
41	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology, 2016, 65, 17-25.	3.7	157
42	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52, 1216-1224.	7.3	156
43	Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 2015, 6, 6422.	12.8	156
44	Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Persons in a Randomized, Controlled Study (CAESAR). Journal of Infectious Diseases, 1999, 180, 607-613.	4.0	145
45	Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study. Journal of Hepatology, 2006, 45, 197-203.	3.7	142
46	Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". Clinical Infectious Diseases, 2015, 60, 1829-1836.	5.8	134
47	Knowledge and Attitudes about Treatment for Hepatitis C Virus Infection and Barriers to Treatment among Current Injection Drug Users in Australia. Clinical Infectious Diseases, 2005, 40, S313-S320.	5.8	133
48	Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. Aids, 2004, 18, 1169-1177.	2.2	132
49	Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. International Journal of Drug Policy, 2017, 47, 209-215.	3.3	130
50	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology, 2003, 32, 717-724.	1.9	129
51	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology and Hepatology, 2018, 3, 125-133.	8.1	128
52	Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 641-651.	17.8	127
53	Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?. Journal of the International AIDS Society, 2017, 20, 22146.	3.0	126
54	Chronic Hepatitis C Is Associated With Peripheral Rather Than Hepatic Insulin Resistance. Gastroenterology, 2010, 138, 932-941.e3.	1.3	124

#	Article	IF	CITATIONS
55	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. The Lancet Gastroenterology and Hepatology, 2017, 2, 514-520.	8.1	123
56	What Is Killing People with Hepatitis C Virus Infection?. Seminars in Liver Disease, 2011, 31, 331-339.	3.6	122
57	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naÃ <sup>-</sup> ve individuals in Thailand. Hepatology, 2008, 48, 1062-1069.	7.3	121

The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and) Tj ETQq0 0 0 rg BT /Overlock 10 Tf

58		5.0	119
59	HIV and hepatitis C coinfection within the CAESAR study. HIV Medicine, 2004, 5, 174-179.	2.2	116
60	Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis. JAMA - Journal of the American Medical Association, 2015, 313, 1736.	7.4	114
61	Impact of Highly Active Antiretroviral Therapy on Individual AIDS-Defining Illness Incidence and Survival in Australia. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 388-395.	2.1	109
62	Characteristics and Treatment Outcomes among HIVâ€Infected Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases, 2009, 48, 650-658.	5.8	109
63	IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 2011, 8, e1001092.	8.4	107
64	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 2016, 7, 12757.	12.8	104
65	Hepatitis <scp>C</scp> disease burden and strategies to manage the burden (Guest Editors Mark) Tj ETQq1 1 0	.784314 r 2.0	gB <u>T</u> /Qverlo
66	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.	3.7	103
66 67	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657. Estimates on <scp>HCV</scp> disease burden worldwide – filling the gaps. Journal of Viral Hepatitis, 2015, 22, 1-5.	3.7 2.0	103 102
66 67 68	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.         Estimates on <scp>HCV</scp> disease burden worldwide – filling the gaps. Journal of Viral Hepatitis, 2015, 22, 1-5.         Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS  study. Medical Journal of Australia, 2014, 201, 326-329.	3.7 2.0 1.7	103 102 101
66 67 68 69	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.         Estimates on <scp>HCV</scp> disease burden worldwide – filling the gaps. Journal of Viral Hepatitis, 2015, 22, 1-5.         Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS  study. Medical Journal of Australia, 2014, 201, 326-329.         Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ: British Medical Journal, 1997, 315, 333-337.	3.7 2.0 1.7 2.3	103 102 101 100
66 67 68 69 70	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.         Estimates on <scp>HCV</scp> disease burden worldwide â€" filling the gaps. Journal of Viral Hepatitis, 2015, 22, 1-5.         Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITSâ€e study. Medical Journal of Australia, 2014, 201, 326-329.         Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ: British Medical Journal, 1997, 315, 333-337.         Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2013, 57, S129-S137.	3.7 2.0 1.7 2.3 5.8	103 102 101 100 99
<ul> <li>66</li> <li>67</li> <li>68</li> <li>69</li> <li>70</li> <li>71</li> </ul>	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.         Estimates on <scp>HCV</scp> disease burden worldwide – filling the gaps. Journal of Viral Hepatitis, 2015, 22, 1-5.         Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITSâ€e study. Medical Journal of Australia, 2014, 201, 326-329.         Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ: British Medical Journal, 1997, 315, 333-337.         Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2013, 57, S129-S137.         Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology, 2008, 48, 398-406.	<ul> <li>3.7</li> <li>2.0</li> <li>1.7</li> <li>2.3</li> <li>5.8</li> <li>7.3</li> </ul>	103 102 101 100 999

#	Article	IF	CITATIONS
73	Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. Clinical Infectious Diseases, 2013, 57, 1014-1020.	5.8	97
74	Disseminated Microsporidiosis Due to Septata intestinalis in Nine Patients Infected with the Human Immunodeficiency Virus: Response to Therapy with Albendazole. Clinical Infectious Diseases, 1995, 21, 70-76.	5.8	96
75	Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research, 2014, 104, 62-72.	4.1	96
76	High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. Journal of Viral Hepatitis, 2007, 14, 413-418.	2.0	95
77	Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases, 2011, 52, 803-811.	5.8	95
78	Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. Aids, 2003, 17, 2191-2199.	2.2	92
79	Continued low uptake of treatment for hepatitis C virus infection in a large communityâ€based cohort of inner city residents. Liver International, 2014, 34, 1198-1206.	3.9	90
80	Estimates of chronic hepatitis B virus infection in Australia, 2000. Australian and New Zealand Journal of Public Health, 2004, 28, 212-216.	1.8	89
81	Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology, 2010, 52, 1564-1572.	7.3	88
82	Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. International Journal of Drug Policy, 2017, 47, 77-85.	3.3	88
83	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. Journal of Infectious Diseases, 2018, 217, 1889-1896.	4.0	88
84	The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence, 2005, 77, 81-86.	3.2	87
85	Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Clinical Infectious Diseases, 2016, 63, 1405-1411.	5.8	87
86	IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis. Nature Genetics, 2017, 49, 795-800.	21.4	86
87	Immunopathogenesis of Hepatic Flare in HIV/Hepatitis B Virus (HBV)–Coinfected Individuals after the Initiation of HBVâ€Active Antiretroviral Therapy. Journal of Infectious Diseases, 2009, 199, 974-981.	4.0	83
88	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 64, 34-46.	7.3	83
89	Is severe liver disease a common outcome for people with chronic hepatitisC?. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 423-430.	2.8	82
90	Predicting progression to cirrhosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2003, 10, 285-293.	2.0	82

#	Article	IF	CITATIONS
91	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology, 2012, 55, 1058-1069.	7.3	82
92	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC <sup>3</sup> Study. Journal of Infectious Diseases, 2015, 212, 1407-1419.	4.0	82
93	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clinical Infectious Diseases, 2016, 63, 1479-1481.	5.8	81
94	Highly endemic hepatitis B infection in rural Vietnam. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 2093-2100.	2.8	80
95	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 317-327.	8.1	80
96	Estimating the cost-effectiveness of needle-syringe programs in Australia. Aids, 2012, 26, 2201-2210.	2.2	79
97	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 163, 809-817.	3.9	79
98	Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 218-230.	17.8	79
99	The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology, 2018, 69, 1188-1196.	3.7	78
100	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Journal of Hepatology, 2019, 71, 281-288.	3.7	76
101	Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1510-1518.	2.8	75
102	Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores. American Journal of Gastroenterology, 2005, 100, 643-651.	0.4	72
103	Primary hepatocellular carcinoma in Australia, 1978â€1997: increasing incidence and mortality. Medical Journal of Australia, 2000, 173, 403-405.	1.7	71
104	Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 2013, 58, 467-472.	3.7	71
105	Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health, 2010, 10, 633.	2.9	69
106	Reinfection with hepatitis C virus following sustained virological response in injection drug users. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1281-1284.	2.8	69
107	Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. Clinical Infectious Diseases, 2013, 56, e87-e94.	5.8	69
108	<scp>HCV</scp> reinfection incidence among individuals treated for recent infection. Journal of Viral Hepatitis, 2017, 24, 359-370.	2.0	68

#	Article	IF	CITATIONS
109	Uptake of directâ€acting antiviral treatment for chronic hepatitis C in Australia. Journal of Viral Hepatitis, 2018, 25, 640-648.	2.0	68
110	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 39-56.	8.1	68
111	Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis <scp>C</scp> â€related liver disease and costs in <scp>A</scp> ustralia. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1-9.	2.8	67
112	Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. Journal of Hepatology, 2019, 70, 33-39.	3.7	66
113	Clearance of Hepatitis C Virus after Newly Acquired Infection in Injection Drug Users. Journal of Infectious Diseases, 2004, 190, 1270-1274.	4.0	65
114	An enormous hepatitis B virusâ€related liver disease burden projected in Vietnam by 2025. Liver International, 2008, 28, 525-531.	3.9	65
115	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 2015, 26, 992-998.	3.3	65
116	Elimination of Hepatitis C Virus in Australia. Infectious Disease Clinics of North America, 2018, 32, 269-279.	5.1	65
117	The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. Journal of Infectious Diseases, 2012, 205, 1342-1350.	4.0	64
118	FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 2016, 64, 390-398.	3.7	64
119	The changing therapeutic landscape for hepatitis C. Medical Journal of Australia, 2012, 196, 629-632.	1.7	64
120	Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug and Alcohol Review, 2012, 31, 918-924.	2.1	63
121	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction, 2016, 111, 311-319.	3.3	63
122	Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al Aids, 2007, 21, 2112-2113.	2.2	62
123	Management of acute HCV infection in the era of direct-acting antiviral therapy. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 412-424.	17.8	62
124	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 2013, 57, 2124-2134.	7.3	61
125	Chronic hepatitis C burden and care cascade in Australia in the era of interferonâ€based treatment. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 229-236.	2.8	61
126	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005â€2014: The <scp>HITS</scp> â€p study. Journal of Viral Hepatitis, 2017, 24, 733-741.	2.0	61

#	Article	IF	CITATIONS
127	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clinical Infectious Diseases, 2017, 64, 860-869.	5.8	61
128	Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology, 2009, 50, 1045-1055.	7.3	60
129	Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. Journal of Hepatology, 2016, 64, 19-28.	3.7	60
130	Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1357-1362.	2.8	59
131	Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption. Aids, 2010, 24, 857-865.	2.2	59
132	Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology, 2014, 60, 1571-1580.	7.3	59
133	A prospective study of hepatitis <scp>C</scp> incidence in Australian prisoners. Addiction, 2014, 109, 1695-1706.	3.3	58
134	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. Journal of Hepatology, 2018, 68, 393-401.	3.7	58
135	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International Journal of Drug Policy, 2018, 62, 14-23.	3.3	58
136	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. Journal of Viral Hepatitis, 2019, 26, 83-92.	2.0	58
137	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. International Journal of Drug Policy, 2018, 61, 23-30.	3.3	57
138	HIV and hepatitis C coinfection. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1000-1008.	2.8	56
139	The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1648-1654.	2.8	56
140	Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. Journal of Viral Hepatitis, 2011, 18, e104-16.	2.0	56
141	Treatment for Hepatitis C Virus Infection among Current Injection Drug Users in Australia. Clinical Infectious Diseases, 2005, 40, S325-S329.	5.8	55
142	Improved cognitive function as a consequence of hepatitis C virus treatment <sup>*</sup> . HIV Medicine, 2007, 8, 520-528.	2.2	55
143	Blood-borne viruses and their survival in the environment: is public concern about community needlestick exposures justified?. Australian and New Zealand Journal of Public Health, 2003, 27, 602-607.	1.8	54
144	Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. Journal of Viral Hepatitis, 2011, 18, 549-561.	2.0	54

#	Article	IF	CITATIONS
145	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	3.3	54
146	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. Clinical Infectious Diseases, 2008, 47, 1468-1475.	5.8	53
147	Treatment of acute HCV infection. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 265-274.	17.8	53
148	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology, 2011, 55, 76-85.	3.7	53
149	Barriers and facilitators for assessment and treatment of hepatitis <scp>C</scp> virus infection in the opioid substitution treatment setting: insights from the <scp>ETHOS</scp> study. Journal of Viral Hepatitis, 2014, 21, 560-567.	2.0	53
150	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical Infectious Diseases, 2020, 71, e115-e124.	5.8	53
151	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	5.8	52
152	Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. Aids, 2009, 23, 1707-1715.	2.2	50
153	Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. International Journal of Drug Policy, 2015, 26, 984-991.	3.3	50
154	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE  II study. Hepatology, 2016, 64, 1911-1921.	7.3	50
155	Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. Clinical Infectious Diseases, 2018, 67, 460-463.	5.8	50
156	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2022, 7, 426-445.	8.1	50
157	Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1082-1086.	2.8	49
158	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. Gastroenterology, 2015, 148, 355-366.e1.	1.3	49
159	Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. Journal of Viral Hepatitis, 2011, 18, 32-41.	2.0	48
160	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. International Journal of Epidemiology, 2013, 42, 1649-1659.	1.9	48
161	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2021, 6, 533-546.	8.1	48
162	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. PLoS ONE, 2015, 10, e0131437.	2.5	48

#	Article	IF	CITATIONS
163	Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. Journal of Hepatology, 2009, 50, 990-998.	3.7	46
164	Case definitions for acute hepatitis C virus infection: A systematic review. Journal of Hepatology, 2012, 57, 1349-1360.	3.7	46
165	Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?. Journal of Hepatology, 2015, 63, 779-782.	3.7	46
166	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Current HIV/AIDS Reports, 2017, 14, 110-121.	3.1	46
167	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. International Journal of Drug Policy, 2018, 54, 18-25.	3.3	46
168	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases, 2020, 71, 1502-1510.	5.8	46
169	Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology, 2011, 54, 879-886.	3.7	45
170	Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1757-1764.	2.8	44
171	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	3.3	44
172	Understanding facilitators and barriers of directâ€acting antiviral therapy for hepatitis C virus infection in prison. Journal of Viral Hepatitis, 2018, 25, 1526-1532.	2.0	44
173	Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy, 2015, 26, 999-1006.	3.3	43
174	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Clinical Infectious Diseases, 2021, 73, e69-e78.	5.8	43
175	Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology, 2010, 53, 616-623.	3.7	42
176	Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 2011, 194, 398-402.	1.7	42
177	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. International Journal of Drug Policy, 2015, 26, 950-957.	3.3	42
178	Global elimination of hepatitis C virus by 2030: why not?. Nature Medicine, 2020, 26, 157-160.	30.7	42
179	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A metaâ€analysis. Hepatology, 2022, 76, 139-154.	7.3	42
180	Surveillance for newly acquired hepatitis C in Australia. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 283-288.	2.8	41

#	Article	IF	CITATIONS
181	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	2.5	41
182	Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals. PLoS ONE, 2013, 8, e61297.	2.5	41
183	Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience. Drug and Alcohol Dependence, 2020, 206, 107705.	3.2	40
184	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre―and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	2.0	39
185	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e107-e118.	5.8	39
186	Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and Alcohol Dependence, 2007, 88, 49-53.	3.2	38
187	Effect of pegylated interferonâ€î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	2.8	38
188	Estimating the number of people who inject drugs in Australia. BMC Public Health, 2017, 17, 757.	2.9	38
189	Treatment adherence and support for people who inject drugs taking directâ€acting antiviral therapy for hepatitis C infection. Journal of Viral Hepatitis, 2019, 26, 1301-1310.	2.0	38
190	Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. Aids, 1996, 10, 1401-1406.	2.2	37
191	Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology, 2011, 53, 1109-1117.	7.3	37
192	Trends in Incidence of AIDS Illnesses in Australia From 1983 to 1994: The Australian AIDS Cohort. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 39-43.	0.3	37
193	Late HIV presentation among AIDS cases in Australia, 1992-2001. Australian and New Zealand Journal of Public Health, 2003, 27, 608-613.	1.8	36
194	Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 116-123.	1.2	36
195	Prevention of Hepatitis C Virus in Injecting Drug Users: A Narrow Window of Opportunity. Journal of Infectious Diseases, 2011, 203, 571-574.	4.0	36
196	Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012. PLoS ONE, 2014, 9, e97726.	2.5	36
197	Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. Journal of Hepatology, 2015, 62, 269-277.	3.7	36
198	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). Journal of Hepatology, 2016, 65, 1086-1093.	3.7	36

#	Article	IF	CITATIONS
199	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infectious Diseases, 2018, 5, ofy001.	0.9	36
200	Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre. Sexual Health, 2007, 4, 27.	0.9	35
201	Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection. Journal of Virology, 2009, 83, 7649-7658.	3.4	35
202	Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. Lancet, The, 2017, 389, 1268-1272.	13.7	35
203	Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection. Aids, 2007, 21, 1555-1559.	2.2	34
204	Prevalence and risk factors for hepatitis C infection in rural north Vietnam. Hepatology International, 2007, 1, 387-393.	4.2	33
205	Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug and Alcohol Dependence, 2010, 107, 244-249.	3.2	33
206	Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 893-898.	3.3	33
207	Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug and Alcohol Dependence, 2019, 194, 487-494.	3.2	33
208	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology, 2017, 92, 32-38.	3.1	32
209	Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development. Journal of Hepatology, 2017, 67, 909-917.	3.7	32
210	Prospective Analysis of Seizures Occurring in Human Immunodeficiency Virus Type-1 Infection. Journal of Neuro-AIDS, 1997, 1, 59-69.	0.2	31
211	Management and Treatment of Injection Drug Users with Hepatitis C Virus (HCV) Infection and HCV/Human Immunodeficiency Virus Coinfection. Seminars in Liver Disease, 2005, 25, 18-32.	3.6	30
212	Liver cancer and hepatitis B and C in New South Wales, 1990–2002: a linkage study. Australian and New Zealand Journal of Public Health, 2007, 31, 475-482.	1.8	30
213	A Comparison of Seminal Hepatitis C Virus (HCV) RNA Levels During Recent and Chronic HCV Infection in HIV-Infected and HIV-Uninfected Individuals. Journal of Infectious Diseases, 2015, 211, 736-743.	4.0	30
214	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology, 2020, 72, 431-440.	3.7	30
215	Hepatitis C virus elimination: laying the foundation for achieving 2030 targets. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 91-92.	17.8	30
216	HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. Aids, 2005, 19, 169-178.	2.2	29

#	Article	IF	CITATIONS
217	Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV–HBV coinfection in Thailand. Antiviral Therapy, 2010, 15, 917-922.	1.0	29
218	Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction, 2011, 106, 977-984.	3.3	29
219	Lipopolysaccharide, Immune Activation, and Liver Abnormalities in HIV/Hepatitis B Virus (HBV)–Coinfected Individuals Receiving HBV-Active Combination Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 210, 745-751.	4.0	29
220	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. Journal of Hepatology, 2016, 65, 879-887.	3.7	29
221	Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy. International Journal of Drug Policy, 2019, 66, 73-79.	3.3	29
222	Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. The Lancet Regional Health - Western Pacific, 2021, 12, 100193.	2.9	29
223	HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Virology, 2010, 405, 539-547.	2.4	28
224	Future of hepatitis C therapy. Current Opinion in HIV and AIDS, 2011, 6, 508-513.	3.8	28
225	Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a populationâ€based cohort study, 1992–2007. Journal of Viral Hepatitis, 2011, 18, e232-41.	2.0	28
226	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 230-238.	3.3	28
227	Poor criterion validity of selfâ€reported hepatitis B infection and vaccination status among injecting drug users: A review. Drug and Alcohol Review, 2009, 28, 669-675.	2.1	27
228	Virological responses during treatment for recent hepatitis C virus. Aids, 2012, 26, 1653-1661.	2.2	27
229	Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 2012, 196, 633-637.	1.7	27
230	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infectious Disease Clinics of North America, 2018, 32, 371-393.	5.1	27
231	An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. International Journal of Drug Policy, 2019, 72, 99-105.	3.3	27
232	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. Journal of Hepatology, 2021, 74, 293-302.	3.7	27
233	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment ofÂrecently acquired hepatitis C infection. Journal of Hepatology, 2021, 75, 829-839.	3.7	27
234	The Effect of Hepatitis C Virus Infection on Health-Related Quality of Life in Prisoners. Journal of Urban Health, 2006, 83, 275-288.	3.6	26

#	Article	IF	CITATIONS
235	Processing of the Bovine Spongiform Encephalopathy-Specific Prion Protein by Dendritic Cells. Journal of Virology, 2006, 80, 4656-4663.	3.4	26
236	Estimates and projections of hepatitis Bâ€related hepatocellular carcinoma in Australia among people born in Asiaâ€Pacific countries. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 922-929.	2.8	26
237	Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug and Alcohol Dependence, 2013, 133, 529-534.	3.2	26
238	Dynamics of HCV RNA levels during acute hepatitis C virus infection. Journal of Medical Virology, 2014, 86, 1722-1729.	5.0	26
239	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2021, 72, 1392-1400.	5.8	26
240	Global cascade of care for chronic hepatitis C virus infection: A systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2021, 28, 1340-1354.	2.0	26
241	Sequencing of hepatitis C virus for detection of resistance to directâ€acting antiviral therapy: A systematic review. Hepatology Communications, 2017, 1, 379-390.	4.3	26
242	Improving survival following AIDS in Australia, 1991–1996. Aids, 2000, 14, 2349-2354.	2.2	25
243	Sequencing of the Hepatitis C Virus: A Systematic Review. PLoS ONE, 2013, 8, e67073.	2.5	25
244	<i>ITPA</i> genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology, 2014, 59, 2152-2160.	7.3	25
245	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent <scp>HCV</scp> genotype 1 infection. Journal of Viral Hepatitis, 2018, 25, 1180-1188.	2.0	25
246	Hepatitis C virus testing, liver disease assessment and directâ€acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 2019, 26, 969-979.	2.0	25
247	Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology, 2008, 48, 741-749.	7.3	24
248	Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the <scp>ETHOS</scp> study. Journal of Viral Hepatitis, 2015, 22, 914-925.	2.0	24
249	Shortâ€Duration Panâ€Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology, 2020, 72, 7-18.	7.3	24
250	Spectrum of AIDS-Defining Illnesses in Australia, 1992 to 1998: Influence of Country/Region of Birth. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 283-290.	2.1	23
251	Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiology and Infection, 2007, 135, 144-150.	2.1	23
252	Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. Aids, 2014, 28, S35-S46.	2.2	23

#	Article	IF	CITATIONS
253	A molecular transmission network of recent hepatitis C infection in people with and without <scp>HIV</scp> : Implications for targeted treatment strategies. Journal of Viral Hepatitis, 2017, 24, 404-411.	2.0	23
254	HIV-1 infection among female commercial sex workers in rural Thailand. Aids, 1997, 11, 89-94.	2.2	22
255	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology, 2009, 49, 1113-1121.	7.3	22
256	Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status. Drug and Alcohol Dependence, 2010, 108, 134-137.	3.2	22
257	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. Journal of Clinical Virology, 2014, 60, 295-300.	3.1	22
258	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 2018, 62, 94-103.	3.3	22
259	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infectious Diseases, 2018, 18, 215.	2.9	22
260	Systematic review with metaâ€analysis: effectiveness of directâ€acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 51, 34-52.	3.7	22
261	The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Current Opinion in Infectious Diseases, 2001, 14, 749-755.	3.1	21
262	Impaired Hepatitis C Virus (HCV)–Specific Interferon-γ Responses in Individuals With HIV Who Acquire HCV Infection: Correlation With CD4+ T-Cell Counts. Journal of Infectious Diseases, 2012, 206, 1568-1576.	4.0	21
263	Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. Antiviral Therapy, 2015, 20, 199-208.	1.0	21
264	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. Journal of Epidemiology and Community Health, 2015, 69, 745-752.	3.7	21
265	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clinical Infectious Diseases, 2018, 66, 20-28.	5.8	21
266	Public health challenges in hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, E83-E90.	2.8	21
267	Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Medical Journal of Australia, 2002, 177, 240-245.	1.7	20
268	Clinicoâ€pathological study of cytomegalovirus (CMV) in AIDS autopsies: underâ€recognition of CMV pneumonitis and CMV adrenalitis. Australian and New Zealand Journal of Medicine, 1995, 25, 503-506.	0.5	19
269	Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. Aids, 1996, 10, 521-525.	2.2	19
270	HIV and AIDS in Aboriginal and Torres Strait Islander Australians: 1992â€1998. Medical Journal of Australia, 2000, 172, 266-269.	1.7	19

#	Article	IF	CITATIONS
271	Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. International Journal of Drug Policy, 2007, 18, 447-451.	3.3	19
272	HCV reinfection studies and the door to vaccine development. Journal of Hepatology, 2009, 51, 628-631.	3.7	19
273	Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. Vaccine, 2014, 32, 5460-5467.	3.8	19
274	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. Journal of Viral Hepatitis, 2018, 25, 473-481.	2.0	19
275	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clinical Infectious Diseases, 2020, 70, 2369-2376.	5.8	19
276	Natural History Models for Hepatitis C-Related Liver Disease: Different Disease Progression Parameters for Different Settings. Antiviral Therapy, 2003, 8, 365-372.	1.0	19
277	Review of antenatal testing policies and practice for HIV and hepatitis C infection. Australian and New Zealand Journal of Public Health, 2003, 27, 614-619.	1.8	18
278	No Increase in Hepatitis B Virus (HBV)-Specific CD8 <sup>+</sup> T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy. Journal of Virology, 2010, 84, 2657-2665.	3.4	18
279	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 2015, 26, 1094-1102.	3.3	18
280	Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. Journal of Hepatology, 2016, 64, 1247-1255.	3.7	18
281	We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States. Journal of Infectious Diseases, 2020, 222, S773-S781.	4.0	18
282	HAART's first decade: success brings further challenges. Lancet, The, 2006, 368, 427-428.	13.7	17
283	Maintenance of <scp>T</scp> h1 hepatitis <scp>C</scp> virus ( <scp>HCV)</scp> â€specific responses in individuals with acute <scp>HCV</scp> who achieve sustained virological clearance after treatment. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1770-1781.	2.8	17
284	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. Journal of Molecular Diagnostics, 2018, 20, 621-627.	2.8	17
285	Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. International Journal of Drug Policy, 2020, 83, 102837.	3.3	17
286	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. Antiviral Therapy, 2011, 16, 667-675.	1.0	16
287	Delivery of treatment for hepatitis C virus infection in the primary care setting. European Journal of Gastroenterology and Hepatology, 2014, 26, 1003-1009.	1.6	16
288	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	4.0	16

#	Article	IF	CITATIONS
289	Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infectious Diseases, 2016, 3, ofw105.	0.9	16
290	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. Journal of Infectious Diseases, 2020, 221, 2043-2049.	4.0	16
291	Modelling and calibration of the hepatitis C epidemic in Australia. Statistical Methods in Medical Research, 2009, 18, 253-270.	1.5	15
292	Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health, 2011, 11, 52.	2.9	15
293	Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney. Australian and New Zealand Journal of Public Health, 2012, 36, 351-356.	1.8	15
294	Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. Journal of Infectious Diseases, 2020, 222, S758-S772.	4.0	15
295	Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. International Journal of Drug Policy, 2021, 96, 103422.	3.3	15
296	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS ONE, 2016, 11, e0150655.	2.5	15
297	Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia. Journal of Hepatology, 2010, 53, 43-49.	3.7	14
298	Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn. Hepatology, 2014, 60, 2127-2128.	7.3	14
299	Distribution of interferon lambdaâ€3 gene polymorphisms in <scp>A</scp> ustralian patients with previously untreated genotype 1 chronic hepatitis <scp>C</scp> : Analysis from the <scp>PREDICT</scp> and <scp>CHARIOT</scp> studies. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 179-184.	2.8	14
300	Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology, 2017, 66, 1101-1103.	3.7	14
301	Phylogenetic analysis of fullâ€length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC <sup>3</sup> Study. Journal of Viral Hepatitis, 2017, 24, 43-52.	2.0	14
302	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infection, Genetics and Evolution, 2019, 71, 36-41.	2.3	14
303	Editorial: Elimination of hepatitis C in Australia by 2030: a decade and counting. Australian Prescriber, 2021, 44, 36-37.	1.0	14
304	A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. Seminars in Liver Disease, 2022, 42, 159-172.	3.6	14
305	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy, 2022, 105, 103706.	3.3	14
306	9.2 Epidemiology of HIV and AIDS in the Asiaâ€Pacific region. Medical Journal of Australia, 1996, 165, 494-498.	1.7	13

#	Article	IF	CITATIONS
307	Estimating <scp>HCV</scp> disease burden – volume 3 (editorial). Journal of Viral Hepatitis, 2015, 22, 1-3.	2.0	13
308	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC <sup>3</sup> study. Journal of Viral Hepatitis, 2015, 22, 708-717.	2.0	13
309	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infection, Genetics and Evolution, 2016, 37, 252-258.	2.3	13
310	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 177-186.	3.3	13
311	Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. PLoS ONE, 2021, 16, e0257369.	2.5	13
312	Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Australian and New Zealand Journal of Public Health, 2004, 28, 576-578.	1.8	12
313	Hepatitis C in AustraliaImpact of a Mass Media Campaign. American Journal of Preventive Medicine, 2006, 31, 492-498.	3.0	12
314	Predictors and survival in hepatitis Bâ€related hepatocellular carcinoma in New South Wales, Australia. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 436-442.	2.8	12
315	Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. Contemporary Clinical Trials, 2009, 30, 431-435.	1.8	12
316	Lower life expectancy among people with an <scp>HCV</scp> notification: a populationâ€based linkage study. Journal of Viral Hepatitis, 2014, 21, e10-8.	2.0	12
317	Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. Journal of Viral Hepatitis, 2019, 26, 1423-1430.	2.0	12
318	Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. Aids, 2020, 34, 1347-1358.	2.2	12
319	Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. International Journal of Drug Policy, 2020, 77, 102693.	3.3	12
320	Epidemiology of hepatitis C virus infection in Australia. Australian Family Physician, 2003, 32, 796-8.	0.5	12
321	Detection of HCV RNA in semen. Lancet, The, 2000, 356, 1520.	13.7	11
322	Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. Journal of Viral Hepatitis, 2010, 17, 896-896.	2.0	11
323	Factors associated with HBV Virological Breakthrough. Antiviral Therapy, 2017, 22, 53-60.	1.0	11
324	Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study. Antiviral Therapy, 2017, 22, 699-710.	1.0	11

#	Article	IF	CITATIONS
325	Analysis of resistanceâ€associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. Journal of Viral Hepatitis, 2017, 24, 37-42.	2.0	11
326	Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus–positive Gay and Bisexual Men?. Clinical Infectious Diseases, 2020, 70, 106-113.	5.8	11
327	Progress Toward Hepatitis C Virus Elimination. Gastroenterology Clinics of North America, 2020, 49, 253-277.	2.2	11
328	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clinical Infectious Diseases, 2022, 75, 1809-1819.	5.8	11
329	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. Journal of Viral Hepatitis, 2015, 22, 1020-1032.	2.0	10
330	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug and Alcohol Dependence, 2016, 169, 156-162.	3.2	10
331	Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection. Journal of Infectious Diseases, 2016, 214, 739-747.	4.0	10
332	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virology Journal, 2016, 13, 32.	3.4	10
333	â€~I didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. International Journal of Drug Policy, 2017, 47, 153-160.	3.3	10
334	Factors Associated with Elevated ALT in an International HIV/HBV Co-Infected Cohort on Long-Term HAART. PLoS ONE, 2011, 6, e26482.	2.5	10
335	Editorial: Observations on the launch of new drugs for hepatitis C. Australian Prescriber, 2018, 41, 4-5.	1.0	10
336	High Effectiveness of Broad Access Directâ€Acting Antiviral Therapy for Hepatitis C in an Australian Realâ€World Cohort: The REACH  Study. Hepatology Communications, 2022, 6, 496-512.	4.3	10
337	Management of chronic hepatitis B in challenging patient populations. Liver International, 2006, 26, 38-46.	3.9	9
338	Low incidence of HCV reinfection: Exposure, testing frequency, or protective immunity?. Hepatology, 2007, 45, 1330-1330.	7.3	9
339	Moving the Agenda Forward: The Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2013, 57, S29-S31.	5.8	9
340	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. PLoS ONE, 2013, 8, e80003.	2.5	9
341	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 2017, 11, 10-18.	2.6	9
342	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab Journal of Gastroenterology, 2018, 19, 26-32.	0.9	9

#	Article	IF	CITATIONS
343	Hepatitis C elimination in Australia: progress and challenges. Medical Journal of Australia, 2020, 212, 362-363.	1.7	9
344	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. Clinical Infectious Diseases, 2021, 73, 2037-2044.	5.8	9
345	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP  Treatment as Prevention Study in Prisons. Hepatology, 2021, 74, 2366-2379.	7.3	9
346	Enhancing hepatitis C treatment uptake and outcomes for injection drug users. Hepatology, 2007, 45, 3-5.	7.3	8
347	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	3.1	8
348	HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection. PLoS ONE, 2016, 11, e0154433.	2.5	8
349	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 2016, 36, 1774-1782.	3.9	8
350	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infection, Genetics and Evolution, 2017, 49, 88-96.	2.3	8
351	Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030. Journal of Hepatology, 2017, 67, 419-420.	3.7	8
352	Estimating <scp>HCV</scp> disease burden—volume 4 (editorial). Journal of Viral Hepatitis, 2017, 24, 4-7.	2.0	8
353	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000â€2014). Hepatology Communications, 2017, 1, 736-747.	4.3	8
354	Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. Journal of Viral Hepatitis, 2021, 28, 710-718.	2.0	8
355	Prescribing of directâ€acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. Medical Journal of Australia, 2021, 215, 332-333.	1.7	8
356	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. Sexual Health, 2020, 17, 223.	0.9	8
357	Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men. PLoS ONE, 2016, 11, e0162002.	2.5	8
358	Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia. Viruses, 2022, 14, 1496.	3.3	8
359	Infant feeding practices and attitudes among women with HIV infection in northern Thailand. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2002, 14, 625-631.	1.2	7
360	Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction. Drug and Alcohol Review, 2007, 26, 437-443.	2.1	7

#	Article	IF	CITATIONS
361	Increased hepatitis <scp>C</scp> virus vaccine clinical trial literacy following a brief intervention among people who inject drugs. Drug and Alcohol Review, 2013, 32, 419-425.	2.1	7
362	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 2019, 9, 1439.	3.3	7
363	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. Clinical Infectious Diseases, 2020, 70, 123-131.	5.8	7
364	Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs. International Journal of Drug Policy, 2021, 93, 102908.	3.3	7
365	Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive. Clinical Infectious Diseases, 2021, 72, 753-754.	5.8	7
366	Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples. Journal of Infectious Diseases, 2021, 223, 818-826.	4.0	7
367	Retreatment for hepatitis C virus directâ€acting antiviral therapy virological failure in primary and tertiary settings: The <scp>REACH </scp> cohort. Journal of Viral Hepatitis, 2022, 29, 661-676.	2.0	7
368	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses, 2022, 14, 1555.	3.3	7
369	Response to Schmutz et al., â€ <sup></sup> Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'. Aids, 2007, 21, 777-778.	2.2	6
370	The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure. Journal of Hepatology, 2008, 49, 305-307.	3.7	6
371	Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 2012, 42, 1175-1186.	3.4	6
372	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	4.2	6
373	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 425-434.	1.0	6
374	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 2017, 17, 420.	2.9	6
375	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. Journal of Medical Virology, 2018, 90, 120-130.	5.0	6
376	A latent class approach to identify multiâ€risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. Journal of the International AIDS Society, 2019, 22, e25222.	3.0	6
377	Genomic variability of withinâ€host hepatitis C variants in acute infection. Journal of Viral Hepatitis, 2019, 26, 476-484	2.0	6
378	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. Infection, Genetics and Evolution, 2019, 69, 76-84.	2.3	6

#	Article	IF	CITATIONS
379	The role of social capital in facilitating hepatitis C treatment scaleâ€up within a treatmentâ€asâ€prevention trial in the male prison setting. Addiction, 2021, 116, 1162-1171.	3.3	6
380	Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or â€reâ€diagnose' infections is effective in Australia. Journal of Viral Hepatitis, 2021, 28, 121-128.	2.0	6
381	Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas. The Lancet Gastroenterology and Hepatology, 2021, 6, 89-90.	8.1	6
382	Epidemiology of HIV and AIDS in the Asia-Pacific region. Medical Journal of Australia, 1996, 165, 494-8.	1.7	6
383	Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment. Drug and Alcohol Dependence, 2022, 235, 109438.	3.2	6
384	Trends in infectious disease mortality in Australia, 1979â€1994. Medical Journal of Australia, 1998, 168, 601-604.	1.7	5
385	Enhancing treatment for hepatitis C among drug users. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 11-13.	17.8	5
386	CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 2013, 14, 286-290.	4.1	5
387	Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health services. Medical Journal of Australia, 2014, 201, 339-342.	1.7	5
388	Disease progression during advanced fibrosis:IL28Bgenotype or HCV RNA levels?. Hepatology, 2014, 59, 1650-1651.	7.3	5
389	Addressing reimbursement disparities for directâ€acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. Journal of Viral Hepatitis, 2016, 23, 664-666.	2.0	5
390	Hepatitis C Virus Treatment and Persons Who Inject Drugs. Annals of Internal Medicine, 2016, 164, 203.	3.9	5
391	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 465-465.	1.0	5
392	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. BMC Infectious Diseases, 2016, 16, 241.	2.9	5
393	<i>Editorial Commentary</i> : Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World―Outcomes. Clinical Infectious Diseases, 2016, 62, 927-928.	5.8	5
394	Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data. BMC Infectious Diseases, 2017, 17, 740.	2.9	5
395	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infectious Diseases, 2018, 5, ofy248.	0.9	5
396	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. Journal of Hepatology, 2019, 70, e733.	3.7	5

#	Article	IF	CITATIONS
397	HCV reinfection as a positive indication of highâ€risk population treatment access. Journal of Viral Hepatitis, 2019, 26, 516-518.	2.0	5
398	Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. Diagnostics, 2021, 11, 1354.	2.6	5
399	All ause hepatocellular carcinoma survival in the era of directâ€acting antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	2.8	5
400	Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?. Hepatology, 2011, 53, 1055-1056.	7.3	4
401	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1458-1462.	2.8	4
402	Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. Hepatology, 2016, 64, 2264-2265.	7.3	4
403	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. Journal of Hepatology, 2019, 70, e231.	3.7	4
404	People with Hepatitis C Who Inject Drugs — Underserved, Not Undeserving. New England Journal of Medicine, 2020, 383, 608-611.	27.0	4
405	Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications, 2020, 4, 904-915.	4.3	4
406	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLOâ€C): An openâ€label, singleâ€arm, phase 4, multicentre trial. Health Science Reports, 2020, 3, e151.	1.5	4
407	HIV and AIDS in the Asia-Pacific region: an epidemiological overview. Aids, 1998, 12 Suppl B, S1-10.	2.2	4
408	Bridging the divide: global inequities in access to HIV/AIDS therapy. Medical Journal of Australia, 2001, 175, 570-572.	1.7	3
409	Mortality in patients with hepatitis B or hepatitis C – Authors' reply. Lancet, The, 2006, 368, 1767.	13.7	3
410	Tell me it ain't so: Patient-to-patient transmission of hepatitis C in an endoscopy clinic. Hepatology, 2008, 48, 1333-1335.	7.3	3
411	The Impact of Ribavirin Plasma Concentration on the Efficacy of the Interferon-Sparing Regimen, Sofosbuvir and Ribavirin. Antiviral Therapy, 2016, 21, 127-132.	1.0	3
412	Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. Journal of Molecular Diagnostics, 2015, 17, 583-589.	2.8	3
413	Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scaleâ€up of directâ€acting antiviral treatment. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2270-2274.	2.8	3
414	Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel. International Journal of Drug Policy, 2021, 98, 103379.	3.3	3

#	Article	IF	CITATIONS
415	Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study. Journal of Viral Hepatitis, 2022, 29, 271-279.	2.0	3
416	Immunity against hepatitis C virus infection. Lancet, The, 2002, 360, 1019-1020.	13.7	2
417	Quality of life of women living with hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1329-1331.	2.8	2
418	Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C. Epidemiology and Infection, 2011, 139, 1151-1158.	2.1	2
419	Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 2012, 17, 849-854.	1.0	2
420	Hepatitis C treatment as prevention among HIVâ€infected men who have sex with men: Feasible?. Hepatology, 2016, 64, 1834-1836.	7.3	2
421	Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godotâ€: Journal of Hepatology, 2018, 68, 616-617.	3.7	2
422	PS-070-Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study. Journal of Hepatology, 2019, 70, e42.	3.7	2
423	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. Journal of Hepatology, 2019, 70, e110.	3.7	2
424	Cure and Control: What Will It Take to Eliminate HCV?. Topics in Medicinal Chemistry, 2019, , 447-490.	0.8	2
425	Universal screening for hepatitis C virus infection should be linked to universal treatment access. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 321-322.	17.8	2
426	Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. Antiviral Therapy, 2003, 8, 365-72.	1.0	2
427	Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. Antiviral Therapy, 2011, 16, 173-180.	1.0	1
428	Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infectious Diseases, 2016, 3, ofw024.	0.9	1
429	Commentary on Gountas et al . (2017): Time to focus on empirical evidence for HCV treatment as prevention. Addiction, 2017, 112, 1300-1301.	3.3	1
430	Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study. Gastroenterology, 2017, 152, S1058-S1059.	1.3	1
431	Striving for hepatitis C virus elimination or control?. The Lancet Gastroenterology and Hepatology, 2018, 3, 295-297.	8.1	1
432	Reply to: "â€~Who killed JR': Chronic hepatitis C or alcohol use disorders?― Journal of Hepatology, 2018, 68, 1099-1100.	3.7	1

25

#	Article	IF	CITATIONS
433	THU-403-The consensus hepatitis C cascade of care: Methodology and initial findings from three countries. Journal of Hepatology, 2019, 70, e333-e334.	3.7	1
434	Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding. The Lancet Gastroenterology and Hepatology, 2020, 5, 1028-1029.	8.1	1
435	Creating an environment for equitable access to directâ€acting antiviral therapy for people who inject drugs with hepatitis C. Liver International, 2020, 40, 2353-2355.	3.9	1
436	Should research ethics change at the border?. Medical Journal of Australia, 1999, 171, 168-168.	1.7	0
437	Reply to Vogel et al Clinical Infectious Diseases, 2009, 49, 319-320.	5.8	0
438	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. International Journal of Drug Policy, 2015, , 101669.	3.3	0
439	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vÃa parenteral. International Journal of Drug Policy, 2015, , 101671.	3.3	0
440	Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs. International Journal of Drug Policy, 2015, 26, 1039-1040.	3.3	0
441	Su1424 Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis. Gastroenterology, 2016, 150, S1096.	1.3	0
442	Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis― Journal of Hepatology, 2019, 71, 1254-1255.	3.7	0
443	HCV Elimination in Australia. , 2021, , 213-227.		0
444	Cost-effectiveness of Treatment for Chronic Hepatitis C Infection. JAMA - Journal of the American Medical Association, 2003, 290, 1993-a-1993.	7.4	0
445	Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study. Canadian Journal of Addiction, 2009, 1, 33.	0.4	0
446	Infectious diseases in the 21st century. Are we entering the hot zone?. Australian Family Physician, 2000, 29, 627-30.	0.5	0